Cholecystokinin cholescintigraphy: methodology and normal values using a lactose-free fatty-meal food supplement

What Was Tested

Researchers studied Cholecystokinin (CCK) in this clinical trial publication.

The purpose of this investigation was to evaluate the use of a commercially available lactose-free fatty-meal food supplement, as an alternative to sincalide cholescintigraphy, to develop a standard methodology, and to determine normal gallbladder ejection fractions (GBEFs) for this supplement.

Who Took Part

The study group was 20 subjects.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Twenty healthy volunteers all had negative medical histories for hepatobiliary and gallbladder disease, had no personal or family history of hepatobiliary disease, and were not taking any medication known to affect gallbladder emptying.

Three of the 20 subjects were eliminated from the final analysis because of an abnormality in one of the above studies.

How the Study Was Run

All were prescreened with a complete blood cell count, comprehensive metabolic profile, gallbladder and liver ultrasonography, and conventional cholescintigraphy.

What Was Measured

Topics PubMed links to this paper include Cholecystokinin, Dietary Fats, Dietary Supplements, Gallbladder, Gallbladder Emptying, Lactose and Metabolic Clearance Rate.

What This Means in Plain Language

This is a clinical trial of Cholecystokinin (CCK) in 20 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2003 (Journal of nuclear medicine : official publication, Society of Nuclear Medicine), a journal based in United States.

More context: the Cholecystokinin (CCK) compound page, all human trials.